PORT 9
Alternative Names: PORT-9; TT-3Latest Information Update: 05 Aug 2022
Price :
$50 *
At a glance
- Originator Impetis Biosciences
- Developer Portage Biotech
- Class Antineoplastics; Immunotherapies; Small molecules
- Mechanism of Action Adenosine A2B receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Colorectal cancer; Gastrointestinal cancer
Most Recent Events
- 01 Aug 2022 Stimunity establishes CRADA with National Cancer Institute for the development of adenosine in Cancer before August 2022
- 19 Aug 2021 Preclinical trials in Colorectal cancer in USA (PO) (Tarus Therapeutics pipeline, August 2021)
- 09 Feb 2021 Preclinical trials in Gastrointestinal cancer in USA (PO) (Tarus Therapeutics pipeline, February 2021)